Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"MIRO" (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab

NCT02710643 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT02710643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02710643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"MIRO" (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
April 7, 2022
Enrollment
110 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma grade 3a, follicular lymphoma, grade 1, follicular lymphoma, grade 2